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OBJECTIVE: Minimally invasive methods are used as alternatives to treat leiomyomas and include uterine artery
embolization, which has emerged as a safe, effective method. This study aims to evaluate the magnetic
resonance imaging predictors for a reduction in leiomyoma volume in patients undergoing uterine artery
embolization.
METHODS: This prospective longitudinal study was performed at a university hospital. We followed 50
symptomatic premenopausal women with uterine leiomyomas who underwent uterine artery embolization.
We examined 179 leiomyomas among these patients. Magnetic resonance imaging was performed one month
before and six months after uterine artery embolization. Two radiologists who specialized in abdominal
imaging independently interpreted the images. Main Outcome Measures: The magnetic resonance imaging
parameters were the uterus and leiomyomas volumes, their localizations, contrast perfusion pattern and node-
to-muscle ratio.
RESULTS: Six months after treatment, the average uterine volume reduction was 38.91%, and the leiomyomas
were reduced by 55.23%. When the leiomyomas were submucosal and/or had a higher node-to-muscle ratio in
the T2 images, the volume reduction was even greater (greater than 50%). Other parameters showed no
association.
CONCLUSIONS: We conclude that symptomatic uterine leiomyomas in patients undergoing uterine artery
embolization exhibit volume reductions greater than 50% by magnetic resonance imaging when the
leiomyomas are submucosal and/or had a high node-to-muscle ratio in the T2 images.
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& INTRODUCTION
Uterine leiomyomas have become an important public
health problem. Uterine leimyomas adversely affect a
woman’s quality of life due to their high prevalence,
symptomatology and adverse effects on fertility (1).
The objective of leiomyoma treatment is symptom control
and/or the re-establishment of reproductive capacity, if
the patient desires. Uterine artery embolization (UAE) has
emerged as an alternative therapy. UAE was initially used
to prepare for surgery, and its safety and effectiveness (2-4)
have led to its use as a first-choice treatment in many cases.
To treat leiomyoma patients with UAE, an accurate
diagnosis is essential. In particular, the care provider must
know the number and size of leiomyomas and which ones
will have the best response.
Ultrasound is the most commonly used test for leio-
myoma diagnosis due to its precision in identifying tumors,
ease of use and low operating cost. However, other imaging
methods are necessary when either the number of leiomyo-
mas or their volume is very large or very small because
measuring each leiomyoma under these circumstances is
difficult (5-6). In these situations, magnetic resonance
imaging (MRI) offers greater diagnostic precision, greater
accuracy and interobserver variation independence (7).
Most studies that have evaluated leiomyoma treatment
with UAE assessed the development of leiomyomas based
on the largest tumor, which may introduce bias into the
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treatment response analysis (8-12). Few authors have
evaluated all of a patient’s tumors (13-14), and those studies
that did had fewer than 31 patients in the study. Several
studies have used MRI to evaluate leiomyoma progression,
but few (13-15) have analyzed the tumor’s pretreatment
characteristics as predictive factors for treatment outcome.
These studies used the T2 signal and the node location. The
objective of this study was to use MRI to evaluate the factors
that predict leiomyoma reduction in patients undergoing
UAE.
& MATERIALS AND METHODS
This prospective longitudinal study included 50 women
with leiomyomas who underwent UAE between September
2008 and August 2009. All patients underwent similar
treatments following the same protocol. This study was
approved and performed according to the hospital’s
Research Ethics Committee.
The inclusion criteria were an ultrasound diagnosis of
uterine leiomyoma, the presence of symptoms (menorrhagia
and/or pelvic pain) as the primary complaint and an
indication for UAE (i.e., desire to keep the uterus and/or
contraindications for surgery). The exclusion criteria were
malignant genital neoplasms, pelvic inflammatory disease,
allergy to iodinated contrast, coagulopathy, renal failure,
vasculitis, pelvic irradiation, pregnancy and a subserosal
leiomyoma with a pedicle smaller than 50% of the diameter
of the fibroid.
The patients were 27 to 44 years old, with an average age
of 36.3 years. Of the 50 patients, 18 (36%) had been pregnant;
10 patients (20%) had had one pregnancy; and eight (16%)
had two or more pregnancies. Twenty-one patients were
white (42%), 13 (26%) were multiethnic and 16 (32%) were
black.
The patients underwent UAE with spinal anesthesia and
were kept under continuous analgesia for 24 hours. They
underwent an MR exam using a high-field scanner (Siemens
Magnetom 3-Tesla, Siemens, Germany). The exam was
divided into two stages. The first stage occurred one month
before UAE, and the second occurred six months after the
procedure. The exams were performed within 10 days after
menstruation.
For these two stages, a standard imaging protocol for
evaluating the female pelvis was used, along with a
diffusion-weighted sequence and dynamic sequences after
paramagnetic contrast to evaluate the perfusion pattern of
myomatous lesions. The images were interpreted indepen-
dently by two radiologists who specialize in abdominal
imaging. The pre- and postprocedure exams were analyzed
randomly, nonsequentially and anonymously to minimize
bias.
Parameters that may have been related to a greater than
50% reduction in the initial volume were evaluated. The
adopted models considered a binary response, specifically
whether there was a reduction of greater than 50% in the
volume.
The leiomyomas were evaluated individually. MR was
used to evaluate the morphology, including the radiological
dimension(s) of the leiomyoma and uterus, and the volume,
which was measured using the formula for an ellipse. The
leiomyoma fibroids were counted, and their locations in the
myometrium were classified as submucosal, intramural or
subserosal. Perfusion and the characterization of the T2
signal were also evaluated.
The contrast perfusion pattern was evaluated in the T1
images using the PP ratio. The peak high-contrast phase
(HCP) and precontrast phase (PCP) are parameters for this
relationship, and the PP ratio = [(HCP fibroid-PCP fibroid)/
PCP fibroid]X100 (16).
Other morphological changes were observed in T2-
weighted sequences, and the images were evaluated when
tissue hydration was sufficient. The T2 signal intensity for
the leiomyoma fibroids and striated muscle, which does not
change with the procedure, and the T2 ratio (i.e., signal
intensity of the fibroid divided by the signal intensity for the
muscle) were evaluated. The T2 signal intensities for
leiomyomas may be different due to the patient’s biotype.
Comparing fibroids from the same patient, which are
interdependent with other fibroids in the uterus, using a
common denominator for each patient’s leiomyomas
becomes necessary. Thus, the T2 fibroid-to-muscle ratio
allowed for the adjustment of these differences and was
significant in a multivariate analysis. The same ratio was
used by Sipola et al. (16), who demonstrated its usefulness
in predicting greater leiomyoma reduction.
The numeric variables are described as means, standard
deviations (SD) and confidence intervals or as medians and
interquartile ranges when the values were not normally
distributed. The qualitative variables are described as
absolute frequencies and percentages. The comparisons
between pre- and postembolization in relation to the uterine
volume and T2-weighted muscle values were analyzed
using the Wilcoxon test.
Univariate and multivariate analyses were conducted to
identify the effects of several factors on the percent
reduction in the fibroid volume. These models were used
to assess the reliability of the measurements taken from
different fibroids from the same patient. For both methods,
variables that showed a p,0.20 in the univariate analysis
were included in the multivariate models. The level of
significance adopted was 0.05. All analyses were performed
using SPSS (version 17.0, SPSS, Inc., Chicago, Ill).
& RESULTS
There were 179 fibroids among the 50 patients. The
patients had a median of three fibroids, with a range of one
to eight, and most fibroids were intramural. The locations of
the fibroids are presented in Table 1.
The median uterine volume was 517 cm3 (312.2 to 648.8
cm3) prior to the procedure and was reduced to 256.5 cm3
(184.0 to 464.0 cm3) after embolization (p,0.001). The uterine
volume reduction in the 50 patients ranged from 0.67 to
93.53%, with an average of 38.91% (95% CI= 33.41-44.41).
The majority of the leiomyoma fibroids (97.7%) showed
a volume reduction after embolization and a reduction in
the T2 signal intensity (Table 2). The percent reduction in
Table 1 - Fibroid classification according to the location in
the myometrium.
Location of fibroid in the myometrium n (%)
Intramural 133 (74.3%)
Subserosal 34 (19.0%)
Submucosal 12 (6.7%)
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fibroid volume ranged from 40.63 to 100%, with a mean of
55.23% and a SD of 31.80%.
The number of fibroids and the uterine and fibroid
volumes before and after embolization were not associated
with a reduction in the fibroid volume (Table 3). The
location of the fibroid in the myometrium, T2 fibroid signal
and PP and T2 node-to-muscle ratios were the variables
selected for the multivariate model. In this mode, the PP
ratio and the T2 fibroid signal were no longer significant.
The multivariate model showed that there was a greater
chance that the fibroid volume decreased by more than 50%
as the T2 fibroid-to-muscle ratio increased (OR: 1.528; 95%
CI: 1.186-2.149; p= 0.015).
Regarding fibroids located in the myometrium, when
the fibroid location was submucosal, a greater than 50%
reduction in its volume was observed.
& DISCUSSION
The patients were monitored for six months based on
studies that showed that the leiomyomas were significantly
reduced during this period (8,13,15).
In the present study and studies by Gabriel-Cox et al. (12)
and Sipola et al. (16), the patient’s age did not correlate with
a reduction in size. In a study by Jha et al. (13), increased age
was a predictor of failure. Emphasizing the difficulty in
comparing the mean ages of the patients across studies is
important; in this study, the mean age was 36.3 years,
whereas in the previously mentioned studies, the mean ages
were 45, 48 and 45 years, respectively. These data become
more important when comparing the long-term results from
studies involving patients who are close to menopause,
when there is a greater likelihood that the symptoms will
resolve (17).
The mean uterine volume (517.7 cm3) in this study was
similar to that described by Gabriel-Cox et al. (12) in a
multicenter study. The present study did not find differ-
ences in volume reduction for different uterine volumes,
which is comparable to the results reported by Gabriel-Cox
et al. (12) and Prollius et al. (18). The leiomyomas were
reduced by 55.23%, and the uterus was reduced by 38.91%,
compared with the 60% and 40% reductions, respectively,
reported in the literature (14,19).
There was no association between leiomyoma size and
volume reduction. Thus, in terms of size reduction, patients
with large leiomyomas and patients with smaller leiomyo-
mas are both good candidates for UAE. Other authors found
similar results based on leiomyoma size (11,14,16,20). When
the leiomyomas were submucosal, there was an increased
reduction in leiomyoma volume in this study. Jha et al. (13)
and de Souza and Williams (21) showed that a greater
volume reduction occured when the leiomyoma was sub-
mucosally located within the uterus compared with other
locations. Spies et al. found that leiomyomas located in the
submucosa were associated with a greater volume reduction
after UAE compared with subserosal leiomyomas (21).
However, this difference did not persist over 12 months. In
another study (18), the location of the leiomyoma did not
have a significant effect on its size reduction; however, in this
sample population, only two of 47 fibroids were submucosal.
In the present study, there was a trend toward a greater
leiomyoma size reduction in the fibroids with a high T2
signal, which is consistent with the findings of de Souza and
Williams (21), Oguchi et al. (22), Burn et al. (14) and Harman
et al. (15); however, Sipola et al. (16) did not find a
significant association (p=0.08) when analyzing this vari-
able. The greatest T2 signal and greatest response could be
related to the leiomyoma’s cellularity and vascularization
Table 2 - Measurement of the fibroid volume and T2 signal intensity before and after embolization.
Before embolization After embolization
Median (IQR) Minimum Maximum Median (IQR) Minimum Maximum
Fibroid volume
(cm3)
21.50 (7.40-81.60) 0.5 703 7.00 (1.00-35.00) 0 449.5
T2 SI for the
fibroid
87.00 (63.00-142.00) 18 390 50.00 (34.00-82.00) 23 388
IQR = interquartile range.
SI = signal intensity.
Table 3 - Univariate and multivariate analyses for factors associated with a volume reduction greater than 50%.
Univariate Multivariate
OR CI (95%) p-value OR CI (95%) p-value
Uterine volume pre-embolization 1.000 (0.999; 1.001) 0.725
Fibroid location in the myometrium
Intramural/submucosal 0.099 (0.010; 0.952) 0.045 0.132 (0.016; 1.095) 0.061
Subserosal/submucosal 0.051 (0.005; 0.526) 0.012 0.056 (0.006; 0.504) 0.010*
Fibroid volume (tertile)
Up to 10 cm3/greater than 56 cm3 1.206 (0.561; 2.594) 0.631
Between 10 and 56 cm3/greater than 56 cm3 1.386 (0.654; 2.937) 0.394
T2 fibroid/muscle ratio 1.262 (1.063; 1.500) 0.008 1.528 (1.086; 2.149) 0.015*
PP ratio 1.005 (0.998; 1.012) 0.167 1.005 (0.998; 1.013) 0.174
T2 fibroid signal intensity 1.004 (0.999; 1.009) 0.080 0.997 (0.988; 1.006) 0.463
Four or fewer fibroids/more than four fibroids 0.637 (0.292; 1.391) 0.258
*p,0.05 (denotes significance).
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(22), but Yamashita et al. (23) stated that some degenerated
leiomyomas had a higher T2 signal intensity and then
greater volume reduction. Therefore, factors other than
degeneration and cellularity, or perhaps the overlap of these
factors, may explain the variability of these results.
The value of the PP ratio, which measures contrast
perfusion, was controversial in our study. This ratio was not
associated with a reduced leiomyoma volume in the
multivariate analysis. This outcome is supported by results
from Burn et al. (14) and de Souza and Williams (21).
Fibroid behavior may follow a different pattern depending
on the vascularization of these fibroids and the adjacent
myometrium; however, this theory is still under study (21).
In the analysis of variables that may be related to
leiomyoma volume reduction, there was no association with
uterine volume, leiomyoma volume, number of fibroids or T2
signal intensity. In a study by Sipola et al. (16), there was also
no relationship between volume reduction and leiomyoma
volume before embolization. Therefore, the present study
showed a greater reduction for higher T2 ratios. Unlike the
present study, the PP ratio described and evaluated here did
not affect treatment outcomes (16).
In this study, the main outcome variable was leiomyoma
volume reduction. The clinical improvement related to
greater volume reduction is still controversial and does not
necessarily correlate with an improvement in clinical
symptoms (21). Additionally, reducing the size of the
submucosal area may be more important for symptomatol-
ogy than the size of the leiomyoma (9). Other authors
showed that size reduction was associated with clinical
outcomes, such as clinical failure, hysterectomy (24) and
symptom recurrence (25). Leiomyoma volume reduction is
an important treatment goal and affects a patient’s progress.
Despite the known interdependence of multiple leiom-
yomas within a patient, most authors have evaluated
leiomyoma progress on the basis of the largest tumor,
whether by analyzing vascular factors (25-26), genetic
factors (27) or growth factors (28). This method may
constitute a bias in the analysis of treatment response
(8-12). Thus, the aforementioned variables (i.e., age and
leiomyoma location) in addition to the use of the dominant
fibroid may complicate comparisons among studies.
Studying the therapeutic alternatives to the conservative
treatment of uterine leiomyoma and the diagnosis of and
indications for these alternatives will lead to a better
understanding of these parameters. Therefore, when coun-
seling and informing patients about conservative and
alternative methods for uterine leiomyoma treatment,
emphasizing that some patients will require new interven-
tions is important. When assessing these interventions, care
providers should try to understand which leiomyomas will
respond the best. Our study reinforces this tendency and
provides new challenges for medical science because the
specialist’s and patient’s understanding of the method are
not widespread. New studies could be performed to
confirm these findings and suggest which parameters
would provide gynecologists and patients with the best
knowledge.
In conclusion, uterine leiomyomas from symptomatic
patients who undergo UAE had a volume reduction greater
than 50% when MRI determined that the fibroids were
submucosal and/or there was a high T2 fibroid/muscle
ratio.
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